Xencor, Inc. (XNCR)

Market Cap	1.66B
Revenue (ttm)	85.16M
Net Income (ttm)	-198.24M
Shares Out	69.98M
EPS (ttm)	-3.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	508,917
Open	23.62
Previous Close	23.63
Day's Range	23.22 - 23.76
52-Week Range	15.31 - 26.84
Beta	0.66
Analysts	Strong Buy
Price Target	35.50 (+49.66%)
Earnings Date	Nov 6, 2024

About XNCR

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 3, 2013
• Employees: 280
• Stock Exchange: NASDAQ
• Ticker Symbol: XNCR
• Website: https://www.xencor.com

Financial Performance

In 2023, Xencor's revenue was $168.34 million, an increase of 2.28% compared to the previous year's $164.58 million. Losses were -$126.09 million, 128.5% more than in 2022.

Analyst Forecast

According to 8 analysts, the average rating for XNCR stock is "Strong Buy." The 12-month stock price forecast is $35.5, which is an increase of 49.66% from the latest price.

Price Target

$35.5

(49.66% upside)

Analyst Consensus: Strong Buy